Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196)

China flag China · Delayed Price · Currency is CNY
27.40
+0.55 (2.05%)
Nov 20, 2024, 11:30 AM CST
-3.42%
Market Cap 65.10B
Revenue (ttm) 41.61B
Net Income (ttm) 2.11B
Shares Out 2.66B
EPS (ttm) 0.78
PE Ratio 34.86
Forward PE 23.21
Dividend 0.27 (1.01%)
Ex-Dividend Date Aug 6, 2024
Volume 11,144,898
Open 26.86
Previous Close 26.85
Day's Range 26.80 - 27.53
52-Week Range 20.38 - 30.44
Beta 0.71
Analysts n/a
Price Target n/a
Earnings Date Oct 28, 2024

About Shanghai Fosun Pharmaceutical (Group)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company’s product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the tr... [Read more]

Sector Healthcare
Founded 1994
Employees 40,370
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600196
Full Company Profile

Financial Performance

In 2023, Shanghai Fosun Pharmaceutical (Group)'s revenue was 41.40 billion, a decrease of -5.81% compared to the previous year's 43.95 billion. Earnings were 2.39 billion, a decrease of -36.04%.

Financial Statements

News

Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse

Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.

1 year ago - Reuters

Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech

Genuine Biotech rec'd China approval on Monday for use of HIV drug in Covid-19 treatment

2 years ago - Forbes

Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal

Shanghai Nuance Pharma in-licensed China and Southeast Asia rights to a respiratory syncytial virus (RSV) vaccine from Copenhagen's Bavarian Nordic in a $225 million deal.

2 years ago - Seeking Alpha

China's health-care sector may be next to face regulatory crackdown, says economist

Dan Wang of Hang Seng Bank (China) says China's public health-care system is still expensive for ordinary people. The country's regulatory reform will be nationwide and have an international impact, s...

3 years ago - CNBC International TV

Pandemic Accelerates China's Drive Into mRNA Treatments

Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases. High efficacy rates in preventing Covid-19 spark rush by Chinese compan...

3 years ago - Seeking Alpha

Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse

Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma...

3 years ago - Seeking Alpha

Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal

CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will co...

3 years ago - Seeking Alpha

Fosun Pharma shares tumble more than 5% as Hong Kong suspends BioNTech Covid vaccinations

Shares of Shanghai Fosun Pharmaceutical Group in Hong Kong plunged more than 5% in Wednesday morning trade.

3 years ago - CNBC